Quality Risk Management Approach for Drug Development and Its Future Prospectives

  • Muthukumar Subramanian
  • Keshamma E.
  • Deepika Janjua
  • et al.
N/ACitations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

These days, finding new marketing authorizations, guaranteeing regulatory compliance, and keeping labour costs competitive are extremely tough. Many pharmaceutical companies also struggle to deal with local regulatory issues and stay up with changes in key pharmaceutical markets. Regulations are thoroughly reviewed before being given to the RA department. This team compiles the most critical prescription information for global approval and marketing. This category accepts both new and revised product submissions. This is mostly handled by the RA department. RA's job is to provide feedback on proposed or disputed legislation. This is a proactive measure. The ICH framework allows for more early intervention. Regulators have a wide range of responsibilities. In the US, the FDA must register and clear the goods with the export company's regulatory professional.

Cite

CITATION STYLE

APA

Muthukumar Subramanian, Keshamma E., Deepika Janjua, Devinder Kumar, Roshan Kumar, Purabi Saha, … Shuaib Rao. (2022). Quality Risk Management Approach for Drug Development and Its Future Prospectives. Journal for Research in Applied Sciences and Biotechnology, 1(3), 166–177. https://doi.org/10.55544/jrasb.1.3.22

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free